PRODUCTS
Companion Diagnostics (CDx)
PRODUCTS
Companion Diagnostics
(CDx)
The LeukoStrat® CDx FLT3 Mutation Assay
The LeukoStrat CDx FLT3 Mutation Assay identifies mutations in the FLT3 gene, allowing physicians and healthcare providers to select the most appropriate treatment or clinical trial for their patients.
The LeukoStrat CDx Kit is a complete solution for FLT3 detection with automated software generating PDF reports inclusive of the mutant to wild type signal ratio. As the companion diagnostic to the RATIFY, ADMIRAL, and QUANTum-R Phase 3 Clinical Trials leading to the respective approvals of midostaurin (US, EU, Switzerland, Australia, South Korea), gilteritinib fumarate (US, JP), and quizartinib hydrochloride (JP), this assay is the only internationally standardized FLT3 mutation test manufactured and validated to meet international regulatory standards.
The LeukoStrat® CDx FLT3 Mutation Assay
The LeukoStrat CDx FLT3 Mutation Assay identifies mutations in the FLT3 gene, allowing physicians and healthcare providers to select the most appropriate treatment or clinical trial for their patients.
The LeukoStrat CDx Kit is a complete solution for FLT3 detection with automated software generating PDF reports inclusive of the mutant to wild type signal ratio. As the companion diagnostic to the RATIFY, ADMIRAL, and QUANTum-R Phase 3 Clinical Trials leading to the respective approvals of midostaurin (US, EU, Switzerland, Australia, South Korea), gilteritinib fumarate (US, JP), and quizartinib hydrochloride (JP), this assay is the only internationally standardized FLT3 mutation test manufactured and validated to meet international regulatory standards.
COMPANION DIAGNOSTICS (CDx)
Related Articles
COMPANION DIAGNOSTICS (CDx)
Related Articles